ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.

F. Shihab,1 Y. Qazi,2 S. Mulgaonkar,3 K. McCague,4 D. Patel,4 V. Peddi,5 D. Shaffer.6

1University of Utah, Salt Lake City, UT
2University of Southern California, Los Angeles, CA
3Barnabas Health, West Orange, NJ
4Novartis Pharmaceuticals Corporation, East Hannover, NJ
5California Pacific Medical Center, San Francisco, CA
6Vanderbilt University, Nashville, TN.

Meeting: 2016 American Transplant Congress

Abstract number: 36

Keywords: Adverse effects, Efficacy, Kidney transplantation

Session Information

Date: Sunday, June 12, 2016

Session Name: Concurrent Session: Kidney Transplant: CNI Minimization

Session Time: 2:30pm-4:00pm

 Presentation Time: 2:54pm-3:06pm

Location: Room 311

Related Abstracts
  • Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients.
  • Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients

We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure at 12 months in a Phase IIIb, multi-center, randomized, open-label non inferiority study (US92).

De novo renal transplant recipients (n=309) received EVR 0.75 mg b.i.d. as starting dose, which was adjusted to maintain a trough level of 3–8 ng/mL. Patients received TAC and prednisone per local guidelines, with TAC dosing adjusted to achieve trough levels of 4–7 ng/mL (0–2 Months [M]), 3–6 ng/mL (2–6 M) and 2–5 ng/mL (6–12 M). Efficacy failure rates (BPAR, graft loss, death, loss to follow-up) and incidence of AEs were assessed at 12 months post-transplant to investigate relationships to time-normalized EVR and TAC exposure.

At 12 months post-transplant, BPAR, graft loss and death had occurred in 19.1%, 1.3% and 1.9% of patients, respectively, and 2.9% were lost to follow-up. The highest rates of BPAR occurred in patients with EVR <3 ng/mL (64.7% vs. 14.0% at 3–8 ng/mL) and in those with TAC <2 ng/mL (50.0% vs. 19.3% at ≥2 ng/mL). The lowest BPAR rates were associated with EVR 6–8 ng/mL (7.8%), regardless of TAC concentration. Graft loss also occurred most frequently in patients with the lowest EVR and TAC concentrations (10.5% and 100%, respectively). BK viral infection was less frequent at higher EVR (≥6 ng/mL) and lower TAC (<5 ng/mL) levels. Wound healing and peripheral edema rates were less frequent with intermediate-to-high TAC or EVR concentrations. New onset diabetes occurred most often at EVR <3 ng/mL and TAC <2 ng/mL, but also at the highest TAC level (≥8 ng/mL). Hypertriglyceridemia and stomatitis were most common at higher levels of TAC (≥5 ng/mL), regardless of EVR trough levels.

These results demonstrate a low incidence of BPAR and graft loss at an EVR trough level of ≥3 ng/mL with TAC concentration above 2 ng/mL in de novo kidney transplant patients at 12 months post-transplant. In addition, the lowest incidence of AEs were observed with EVR concentrations ≥6 ng/mL with TAC concentrations below 5 ng/mL.

CITATION INFORMATION: Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi V, Shaffer D. Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi V, Shaffer D. Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/relationship-between-clinical-events-and-everolimus-exposure-at-12-months-in-de-novo-renal-transplant-recipients/. Accessed February 26, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.